
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson's innovative medicine division generated revenues of $15.20 billion, reflecting a 2.4% year-over-year increase, which surpassed consensus expectations, indicating strong demand particularly in immunology, oncology, and neurology. Management has raised FY25 reported sales guidance to a range of $93.2–$93.6 billion, supported by approximately $900 million from operational growth and $1.1 billion attributable to favorable currency exchange rates, underscoring the firm's robust financial performance. Additionally, total operational sales growth is expected to accelerate in the second half of 2025 and into 2026, suggesting positive momentum for both top-line and bottom-line growth moving forward.
Bears say
Johnson & Johnson's stock outlook appears negative primarily due to expected revenue pressures from the pharmaceutical pipeline, with projections indicating potential sales declines below $57B by 2025 due to lower contributions and loss of exclusivity for key products. The MedTech division faces significant competitive headwinds and an uncertain integration from mergers and acquisitions, which could hinder expected product uptake and overall growth. Furthermore, increased litigation costs and the unpredictability within the MedTech segment contribute to an unfavorable growth environment, raising concerns for the company's financial stability in the near future.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares